| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Medical Research Service, Seattle Veterans Affairs and Harborview Medical Centers, and Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Washington School of Medicine, Seattle, WA 98195
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The chemotactic cytokines (chemokines) are potent and specific
chemoattractants for inflammatory cells 3 . The CXC chemokines
comprise several proteins that are regulated and produced by resident
cells in the lungs and other organs. These include IL-8, the epithelial
cell-derived neutrophil activator (ENA-78), and the GRO subfamily of
proteins (GRO-
, GRO-ß, and GRO-
). Their critical role in PMN
migration has been shown in humans and in animal models of disease
4, 5, 6, 7, 8, 9, 10, 11 . The redundancy of these host-derived signals for PMN
recruitment complicates the selection of therapeutic targets to reduce
inflammation.
In contrast to the multiple CXC chemokines, only two CXC chemokine
receptors, CXCR1 and CXCR2 (also known as IL-8RA and IL-8RB), have been
shown to mediate the responses to CXC chemokines in PMN 12, 13, 14, 15, 16 . The
two receptors have different ligand binding affinities. CXCR1 binds
with high affinity to IL-8, but binds with low affinity to ENA-78,
neutrophil-activating peptide-2, and GRO-, -ß, and -, whereas,
CXCR2 binds all these CXC chemokines with high affinity 17, 18, 19 .
Moreover, the surface expression of the two CXCRs is regulated
differently in vitro 20, 21 . On unstimulated PMN the two receptors
are expressed in approximately equal numbers, and in the presence of
stimulating ligand both receptors are rapidly internalized. However,
CXCR1 is rapidly re-expressed (within minutes), whereas the
re-expression of CXCR2 is considerably slower. Thus, the expected net
effect of stimulation of PMN with a CXC chemokine is down-regulation of
CXCR2. Even though IL-8 binds both CXCRs with high affinity, blockade
of CXCR1 alone is sufficient to suppress the chemotactic activity of
normal PMN toward IL-8 in vitro 22, 23 . The relevance of these
receptor mechanisms and their effects on CXCR expression on circulating
PMN in vivo in patients with sepsis is unknown, but the available data
suggest that CXCR1 may be a rational target for therapeutic
interventions, particularly in patients with elevated blood levels of
CXC chemokines.
Therefore, we investigated the expression and function of CXCR1 and
CXCR2 in patients with severe sepsis. We hypothesized that in
circulating PMN 1) CXCR2 would be down-regulated; 2) CXCR2
down-regulation would be associated with blunted chemotactic responses
to the CXC chemokines, which depend on CXCR2 for signal transduction
(e.g., ENA-78 and GRO-, -ß, and -); and 3) blockade of CXCR1
alone would be sufficient to block chemotactic activity toward IL-8
despite the ability of IL-8 to engage either receptor. Further, we
hypothesized that CXCR1 blockade would not affect PMN migration toward
other relevant chemoattractants such as the bacterial-derived
chemoattractant, FMLP, or the chemotactically active complement
fragment, C5a, both of which bind distinct receptors on PMN
24, 25, 26 . Herein, we present data supporting these
hypotheses. These data simplify our understanding of the molecular
mechanisms for PMN recruitment in patients with sepsis and organ
failure, and offer a rationale for targeting CXCR1 to block
chemokine-mediated PMN migration while potentially preserving PMN
recruitment to sites of bacterial infection.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Patients in the intensive care units of Harborview Medical Center (Seattle, WA) were prospectively identified between December 1996 and April 1997 as having severe sepsis and organ dysfunction according to the American College of Chest Physicians/Society for Critical Care Medicine Consensus Conference definitions 27 . Criteria for organ dysfunction were specifically defined. Patients had respiratory dysfunction if they met criteria for either ARDS or acute lung injury according to the American/European Consensus Conference definitions 28 . Cardiovascular dysfunction was defined as systemic vascular resistance <800 dyne-s/cm2, systolic blood pressure <90 mm Hg, or need for vasopressors. Hematologic dysfunction was defined as thrombocytopenia (platelets <80K) or disseminated intravascular coagulation. Renal dysfunction was defined as urine output of <30 ml/h and an abrupt rise in creatinine. Hepatic dysfunction was defined as serum bilirubin >3.5 mg/dl. Metabolic dysfunction was defined as an unexplained anion gap >15 mEq/l or serum lactate >2 mmol/l. Central nervous system dysfunction was defined as a Glascow coma scale value <12 unexplained by sedation. Patients were excluded if they were <18 yr of age, pregnant, neutropenic (<1000 white blood cells/µl), recently transfused (>3 U of blood within the preceding 24 h), known to have HIV infection, or entered into an interventional trial designed to ameliorate the systemic inflammatory response before sample acquisition. All subjects were enrolled within 96 h of the onset of severe sepsis and met the entry criteria at the time of enrollment. Eight normal nonsmoking volunteers served as controls. The study protocol was approved by the University of Washington human subjects committee, and informed consent was obtained from all subjects.
Neutrophil isolation
Heparinized blood (40 ml) was obtained and transported immediately on ice to the laboratory. Plasma was obtained from an aliquot of heparinized blood within 20 min of acquisition and was stored at -20°C for subsequent analysis of chemokine concentrations by immunoassay. The remainder of the whole blood was layered onto a Ficoll-Hypaque density gradient (Mono-Poly Resolving Medium, ICN Biomedicals, Costa Mesa, CA), and neutrophils were isolated by centrifugation. RBC were eliminated by hypotonic lysis and dextran sedimentation. Each subject’s neutrophil sample was divided, and half was used for determination of CXCR1 and CXCR2 expression by flow cytometry. The other half was used for measurement of chemotaxis in vitro.
Flow cytometry
PMN were suspended at a concentration of 1 x 106 cells/ml in ice-cold HBSS containing 0.1% NaN3 and 0.1% BSA. To detect CXCR1, PMN were incubated with 1 µg/ml of mouse IgG2b mAb that is specific for CXCR1 22 . Anti-protein C mouse IgG2b Ab (Sigma, St. Louis, MO) served as a control for nonspecific binding. FITC-conjugated goat anti-mouse IgG F(ab')2 (Jackson ImmunoResearch Laboratories, West Grove, PA) was used as a detecting Ab. To detect CXCR2, PMN were incubated with 10 µg/ml of an affinity-purified polyclonal rabbit IgG F(ab')2 that is specific for CXCR2 22 . Nonimmune rabbit IgG F(ab')2 was used as a control, and FITC-conjugated goat anti-rabbit IgG F(ab')2 was used as the detecting Ab (both from Jackson ImmunoResearch Laboratories). Flow cytometry was performed using a FACScan instrument (Becton Dickinson, Mountain View, CA) as previously described 22 .
Neutrophil chemotaxis
PMN chemotaxis was measured as previously described 29 . Briefly, PMN were labeled with 5 µM calcein-AM (Molecular Probes, Eugene, OR) and diluted to a concentration of 3 x 106 cells/ml in RPMI 1640 medium (Sigma). PMN chemotactic activity for IL-8 is maximal between 10–100 nM in this assay. PMN migration was detected by measuring the fluorescence (Cytofluor II, PerSeptive Biosystems, Framingham, MA) of calcein-labeled PMN migrating through an 8.0-µm pore size polyvinylpyrrolidone-free polycarbonate filter during a 90-min incubation in a 96-well chemotaxis chamber (NeuroProbe, Cabin John, MD). Zymosan-activated human serum (ZAS; 10%; containing 1 x 10-8 M C5a by RIA) and FMLP (Calbiochem, San Diego, CA) served as positive controls, and PBS served as a negative control. All samples were tested in triplicate.
Inhibition of chemotaxis was determined in the presence or the absence of an affinity-purified polyclonal rabbit IgG specific for CXCR1 that blocks binding of IL-8 to the CXCR1 receptor 22 . PMN were incubated for 20 min at room temperature in the presence of 50 µg/ml of blocking Ab or nonimmune rabbit IgG (Jackson ImmunoResearch Laboratories). This concentration of anti-CXCR1 Ab is sufficient to block binding of 1 x 10-8 M IL-8 to cloned CXCR1 by competitive radioligand binding 22 . The chemotactic index represents the percentage of the total PMN migrating. It was calculated from the mean fluorescence of PMN migrating toward chemoattractant (IL-8, ZAS, or FMLP) minus the mean fluorescence of PMN migrating to PBS divided by the mean fluorescence of chambers containing 3 x 106 calcein-labeled PMN/ml (total cells available for migration) multiplied by 100. All conditions were tested in triplicate, and the values were averaged.
Plasma chemokine determinations
Plasma concentrations of IL-8, GRO-, and ENA-78 were
determined in 11 patients and 5 normal subjects by sandwich ELISA
according to the manufacturer’s protocol (R & D Systems, Minneapolis,
MN). Specimens with undetectable chemokine concentrations were assigned
a value equal to the lower limit of detection to permit statistical
analysis. Samples were stored at -20°C until assayed, and each
sample was assayed in duplicate.
Statistical analysis
The expression of CXCR1 and CXCR2 on patient and normal PMN was compared using Student’s unpaired t test with unequal variance. Chemotaxis dose-response curves were compared by ANOVA with a Bonferroni/Dunn post-hoc analysis. Chemokine concentrations in plasma of patients and normal volunteers were compared using the Mann-Whitney U test for nonparametric data. Correlations between chemokine concentrations were determined using Spearman’s rank correlation. In all cases, p < 0.05 was accepted as significant.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We studied 14 patients and 8 normal subjects. The causes of sepsis
and the number of dysfunctional organ systems are shown in Table I
. The patients were critically ill, with
APACHE II scores of 25.4 ± 10 (mean ± SD) and a 28-day
mortality rate of 57%.
|
CXCR1 and CXCR2 receptors were identified by flow cytometry. Fig. 1 compares receptor expression on PMN
from a normal volunteer and a septic patient. The expression of CXCR1
was only slightly reduced, whereas the expression of CXCR2 was markedly
reduced on the PMN from this septic patient. Similar changes were seen
for each subject. The CXCR1 fluorescence intensity was normal (i.e.,
±1 SD of the mean of CXCR1 fluorescence on PMN from normal donors) in
nine of 14 septic patients, was reduced in four, and was increased in
one. In contrast, CXCR2 fluorescence intensity was normal in only three
of 14 septic patients and was significantly reduced (reduced by >1 SD
from the mean of CXCR2 fluorescence on PMN from normal donors) in 11 of
14 septic patients.
|
). CXCR1 expression on PMN from septic
patients was not significantly different from that on normal PMN. By
contrast, CXCR2 expression was significantly reduced
(p < 0.005) on PMN from septic patients.
Similar differences were seen when the data were expressed as the fold
increase over control fluorescence. Thus, in contrast to the normal
expression of CXCR1 receptor, CXCR2 receptor is significantly
down-regulated on circulating PMN from septic patients.
|
The migration of PMN from 12 septic patients and seven normal
donors toward five different CXC chemokines was measured (Fig. 3). The chemokine concentrations selected
fell within a biologically relevant range 8 . All the CXC chemokines
were effective chemoattractants for PMN from normal subjects (Fig. 3, A–E, filled circles). The migratory response to IL-8 was
robust in PMN from normal donors and septic patients (Fig. 3A). In contrast, PMN from septic patients demonstrated
significantly reduced chemotactic activity to GRO-, GRO-ß,
GRO-, and ENA-78 (Fig. 3, B–E, open circles), the
chemokines that bind with high affinity to only CXCR2. These data
indicate that the down-regulation of CXCR2 on PMN from septic patients,
seen by flow cytometry (Fig. 2
), is functionally significant.
|
PMN from 14 septic patients and eight normal donors were incubated
in the presence of nonimmune rabbit IgG (50 µg/ml) or
affinity-purified rabbit anti-human CXCR1 polyclonal IgG (50
µg/ml). This concentration of Ab is sufficient to block binding of
radiolabeled IL-8 (up to 1 x 10-8 M) to recombinant
CXCR1 expressed on BHK cells, and the Ab does not recognize CXCR2 22 .
PMN chemotaxis to 1 x 10-8-M concentrations of IL-8,
FMLP, or 10% ZAS (which contained 1 x 10-8 M C5a)
was measured. Anti-CXCR1 significantly inhibited the migration of
normal and septic PMN to IL-8 (p < 0.005), but
the inhibitory effect was more pronounced with septic PMN (Fig. 4). Anti-CXCR1 inhibited chemotaxis of
normal PMN by 42%, but inhibited chemotaxis of septic PMN by 73%. As
expected anti-CXCR1 had little effect on chemotaxis to FMLP or ZAS.
Although CXCR1 Ab produced a slight reduction in chemotaxis of normal
PMN to FMLP, which reached statistical significance in this series of
experiments (p = 0.05), the magnitude of the
effect was minimal (20% decrease), and the effect was not seen in
previous experiments with this or other concentrations of FMLP 22 .
There was no significant effect of the Ab on FMLP-induced migration of
PMN from septic patients. These data show that despite the septic
condition of these patients, their PMN had normal chemotactic responses
to FMLP and C5a and only a slightly reduced response to IL-8. In PMN
from septic patients, blockade of CXCR1 substantially impaired the
migratory response to IL-8 without affecting migratory responses to
FMLP or C5a.
|
Plasma concentrations of IL-8, GRO-, and ENA-78 were determined
by immunoassay in plasma from 11 septic patients and five normal donors
(Fig. 5). The median concentration of
IL-8 in plasma from septic patients was 0.157 ng/ml (19 pM), whereas
levels were undetectable in all five normal subjects
(p < 0.005). The median concentration of
GRO- was 0.170 ng/ml (20 pM) in plasma from septic patients compared
with 0.030 ng/ml (4 pM) in that from normal subjects
(p = 0.07). By contrast, the median
concentration of ENA-78 was 0.140 ng/ml in plasma from septic patients,
which was not significantly different from values in plasma from normal
subjects. Thus, the clinical selection criteria of severe sepsis
identified patients with elevated plasma concentrations of IL-8 and
GRO-, whereas plasma concentrations of ENA-78 were normal in
patients with sepsis. As predicted, there were inverse relationships of
CXCR2 expression with plasma IL-8 levels (r = -0.44)
and with plasma GRO- levels (r = -0.53); however,
the number of patients was insufficient to reach statistical
significance (p = 0.17 and p =
0.09, respectively).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
,
-ß, and - and ENA-78) were markedly suppressed in PMN from septic
patients, whereas the chemotactic response to IL-8, which binds with
high affinity to either CXCR, was preserved. Finally, specific blockade
of CXCR1 had a more pronounced suppressive effect on the chemotactic
function of PMN from septic patients than on that of PMN from normal
donors. Taken together, these observations indicate that CXCR2 is
functionally down-regulated in severe sepsis, leaving CXCR1 as the
dominant receptor for mediating the effects of the CXC chemokines in
PMN from these patients. Previous reports 13, 21, 30 demonstrate that in normal PMN, CXC receptors are transiently internalized following in vitro stimulation by IL-8. Subsequently, CXCR1 is rapidly re-expressed on the cell surface, whereas CXCR2 is re-expressed at a considerably slower rate 21 . The primary rationale for this study was to investigate the relevance of these in vitro observations for patients whose circulating PMN were stimulated in vivo by an active inflammatory process. We prospectively defined a population of patients with severe sepsis and organ dysfunction that we predicted would have elevated circulating chemokine concentrations. We found chemokine values that were elevated to an extent similar to those reported by others 31, 32, 33, 34 . Moreover, we found that CXCR2 was significantly down-regulated in these patients. In addition, there were trends suggesting that higher plasma chemokine concentrations are correlated with lower CXCR2 surface expression. The plasma chemokine concentrations were considerably less than those required for receptor down-regulation in vitro 21 , suggesting that CXCR2 may be modulated by very low chemokine concentrations in vivo in patients with severe sepsis.
Other mechanisms may also contribute to the down-regulation of CXCR2 in
patients with severe sepsis. Cytokines such as TNF- have been
detected in the plasma of septic patients 35 and can down-regulate
CXCRs on PMN in vitro 36 . TNF- may also induce proteolytic
degradation of CXCR2 37 . Hypoxic conditions in vitro can affect PMN
cell surface expression of CXCRs 38 . Granulocyte CSF up-regulates the
transcription and expression of both receptors, and LPS down-regulates
each receptor by decreasing transcription and reducing the half-lives
of their mRNAs 36 . In the complex cytokine milieu of sepsis, all
these mechanisms may contribute to CXCR expression on PMN. Our studies
were designed to examine the net effect of these multiple mechanisms of
CXCR regulation on circulating PMN in vivo under clinically relevant
conditions. We found that CXCR2 expression and function are
down-regulated on circulating PMN from patients with sepsis.
Our observations are relevant to the mechanisms of PMN emigration from the bloodstream in patients with severe sepsis and organ dysfunction. Although Soejima and colleagues 39 showed in chronic stable lung disease that CXCR down-regulation can occur as a result of the process of migration, we have shown that changes in receptor expression occur on circulating PMN even before they migrate into the tissues in critically ill patients with systemic inflammation.
Multiple CXC chemokines are produced in the organ tissues of septic
patients. For example, patients with sepsis-related ARDS have
significantly increased concentrations of IL-8, ENA-78, and GRO- in
their bronchoalveolar lavage fluids 8, 40 . Interestingly, in patients
with ARDS, the average concentrations of ENA-78 and GRO are higher
than that of IL-8 8, 40 . A similarly broad spectrum of CXC chemokines
is produced by macrophages simply by stimulation with endotoxin in
vitro 41 . Another important CXC chemokine, granulocyte chemotactic
peptide-2, binds with high affinity to CXCR1 and is a potent
chemoattractant for PMN, although its characterization in clinical
fluids is limited 42, 43, 44 . The host-derived signals for PMN
recruitment to tissues appear to be highly redundant.
Despite the multiplicity of CXC chemokines, however, the data presented
here suggest that the GRO proteins and ENA-78 may contribute little to
PMN recruitment in septic patients. GRO-, -ß, and - and ENA-78
bind to and signal via CXCR2 17 . In keeping with this, the chemotaxis
of normal PMN to GRO- (10 nM) is inhibited only by Abs to CXCR2, not
by Abs to CXCR1 23 . Our observations extend these findings and
demonstrate their relevance to human disease. It is likely that
down-regulation of CXCR2 expression in vivo contributes significantly
to the suppressed chemotaxis responses to the GRO proteins and ENA-78
that we measured. Regardless of the mechanism, PMN from septic patients
respond poorly to the cognate ligands of CXCR2 when ligands are present
at concentrations 
10 nM. This may help explain the success of
therapeutic interventions targeting only IL-8 in some animal models of
inflammation 9, 10, 11 .
Ab inhibition of CXCR1 was functionally more effective in PMN from patients with sepsis than in normal PMN. IL-8 can bind with high affinity and stimulate chemotaxis via either CXCR 17 , although it stimulates chemotaxis of normal PMN largely via CXCR1 22, 23 . The present studies confirm this prior finding in normal PMN. Additionally, we demonstrated that chemotaxis of PMN from patients with sepsis is more profoundly inhibited than that of normal PMN in the presence of CXCR1 Ab. These experiments further support the functional significance of CXCR2 down-regulation in septic PMN. Chemotaxis to FMLP was well preserved in septic PMN and, as expected, was minimally affected by CXCR1 blockade.
Thus, we have shown that CXCR2 is functionally down-regulated in patients with severe sepsis, perhaps in part by ligand-induced receptor internalization occurring in the circulation, yet CXCR1 remains functional with normal cell surface expression. These data simplify an otherwise complex and redundant system of CXC chemokines and receptors and focus attention on the importance of CXCR1 in sepsis. These studies suggest that a CXCR1 receptor-targeted strategy to limit inflammation in patients with sepsis will reduce PMN migration to CXC chemokines, yet preserve PMN responsiveness to bacterial products.
|
Acknowledgments |
|---|
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. Richard B. Goodman, Veterans Affairs Medical Center, 111B; 1660 S Columbian Way; Seattle, WA 98108. E-mail address:
3 Abbreviations used in this paper: PMN, polymorphonuclear neutrophils; ARDS, acute respiratory distress syndrome; ENA-78, epithelial cell-derived neutrophil activator; GRO, growth-related oncogene; ZAS, zymosan-activated human serum.
Received for publication August 18, 1998. Accepted for publication November 5, 1998.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
, GRO-ß, GRO-, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J. Biol. Chem. 271:20545. in septic shock and septic adult respiratory distress syndrome. Am. Rev. Respir. Dis. 138:1377.[Medline]
. J. Immunol. 160:4518. and interleukin-8 in Pneumocystis carinii or bacterial pneumonia and adult respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 152:1549.[Abstract]
This article has been cited by other articles:
|
|
 |
|
  A. Pachot, M.-A. Cazalis, F. Venet, F. Turrel, C. Faudot, N. Voirin, J. Diasparra, N. Bourgoin, F. Poitevin, B. Mougin, et al. Decreased Expression of the Fractalkine Receptor CX3CR1 on Circulating Monocytes as New Feature of Sepsis-Induced Immunosuppression J. Immunol., May 1, 2008; 180(9): 6421 - 6429. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Rigamonti, C. Fontaine, B. Lefebvre, C. Duhem, P. Lefebvre, N. Marx, B. Staels, and G. Chinetti-Gbaguidi Induction of CXCR2 Receptor by Peroxisome Proliferator-Activated Receptor {gamma} in Human Macrophages Arterioscler. Thromb. Vasc. Biol., May 1, 2008; 28(5): 932 - 939. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zheng, C.-n. Njauw, and M. Martins-Green A hCXCR1 transgenic mouse model containing a conditional color-switching system for imaging of hCXCL8/IL-8 functions in vivo J. Leukoc. Biol., November 1, 2007; 82(5): 1247 - 1256. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Rios-Santos, J. C. Alves-Filho, F. O. Souto, F. Spiller, A. Freitas, C. M. C. Lotufo, M. B. P. Soares, R. R. dos Santos, M. M. Teixeira, and F. de Queiroz Cunha Down-regulation of CXCR2 on Neutrophils in Severe Sepsis Is Mediated by Inducible Nitric Oxide Synthase-derived Nitric Oxide Am. J. Respir. Crit. Care Med., March 1, 2007; 175(5): 490 - 497. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. A. Arraes, M. S. Freitas, S. V. da Silva, H. A. de Paula Neto, J. C. Alves-Filho, M. A. Martins, A. Basile-Filho, B. M. Tavares-Murta, C. Barja-Fidalgo, and F. Q. Cunha Impaired neutrophil chemotaxis in sepsis associates with GRK expression and inhibition of actin assembly and tyrosine phosphorylation Blood, November 1, 2006; 108(9): 2906 - 2913. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. L. Rittner, S. A. Mousa, D. Labuz, K. Beschmann, M. Schafer, C. Stein, and A. Brack Selective local PMN recruitment by CXCL1 or CXCL2/3 injection does not cause inflammatory pain J. Leukoc. Biol., May 1, 2006; 79(5): 1022 - 1032. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Gasser, A. Missiou, C. Eken, and C. Hess Human CD8+ T cells store CXCR1 in a distinct intracellular compartment and up-regulate it rapidly to the cell surface upon activation Blood, December 1, 2005; 106(12): 3718 - 3724. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-M. Cavaillon, C. Adrie, C. Fitting, and M. Adib-Conquy Reprogramming of circulatory cells in sepsis and SIRS Innate Immunity, October 1, 2005; 11(5): 311 - 320. [Abstract] [PDF]
|
|
|
|
|
|
M. H. Tarlowe, A. Duffy, K. B. Kannan, K. Itagaki, R. F. Lavery, D. H. Livingston, P. Bankey, and C. J. Hauser Prospective Study of Neutrophil Chemokine Responses in Trauma Patients at Risk for Pneumonia Am. J. Respir. Crit. Care Med., April 1, 2005; 171(7): 753 - 759. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Ness, K. J. Carpenter, J. L. Ewing, C. J. Gerard, C. M. Hogaboam, and S. L. Kunkel CCR1 and CC Chemokine Ligand 5 Interactions Exacerbate Innate Immune Responses during Sepsis J. Immunol., December 1, 2004; 173(11): 6938 - 6948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Strassburg, D. Droemann, G. van Zandbergen, H. Kothe, and K. Dalhoff Enhanced PMN response in chronic bronchitis and community-acquired pneumonia Eur. Respir. J., November 1, 2004; 24(5): 772 - 778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Chen, R. Mo, P. A. Lescure, D. E. Misek, S. Hanash, R. Rochford, M. Hobbs, and R. L. Yung Aging Is Associated With Increased T-Cell Chemokine Expression in C57Bl/6 Mice J. Gerontol. A Biol. Sci. Med. Sci., November 1, 2003; 58(11): B975 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. L. Ness, C. M. Hogaboam, R. M. Strieter, and S. L. Kunkel Immunomodulatory Role of CXCR2 During Experimental Septic Peritonitis J. Immunol., October 1, 2003; 171(7): 3775 - 3784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Tarlowe, K. B. Kannan, K. Itagaki, J. M. Adams, D. H. Livingston, and C. J. Hauser Inflammatory Chemoreceptor Cross-Talk Suppresses Leukotriene B4 Receptor 1-Mediated Neutrophil Calcium Mobilization and Chemotaxis After Trauma J. Immunol., August 15, 2003; 171(4): 2066 - 2073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. P. Keane, S. C. Donnelly, J. A. Belperio, R. B. Goodman, M. Dy, M. D. Burdick, M. C. Fishbein, and R. M. Strieter Imbalance in the Expression of CXC Chemokines Correlates with Bronchoalveolar Lavage Fluid Angiogenic Activity and Procollagen Levels in Acute Respiratory Distress Syndrome J. Immunol., December 1, 2002; 169(11): 6515 - 6521. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Doroshenko, Y. Chaly, V. Savitskiy, O. Maslakova, A. Portyanko, I. Gorudko, and N. N. Voitenok Phagocytosing neutrophils down-regulate the expression of chemokine receptors CXCR1 and CXCR2 Blood, September 18, 2002; 100(7): 2668 - 2671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Chishti, J. H. Dark, P. Kesteven, H. Powell, C. Snowden, B. K. Shenton, J. A. Kirby, and S. V. Baudouin Expression of chemokine receptors CXCR1 and CXCR2 during cardiopulmonary bypass J. Thorac. Cardiovasc. Surg., December 1, 2001; 122(6): 1162 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.C. Glynn, E.M. Henney, and I.P. Hall Peripheral blood neutrophils are hyperresponsive to IL-8 and Gro-{alpha} in cryptogenic fibrosing alveolitis Eur. Respir. J., September 1, 2001; 18(3): 522 - 529. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. J. Mackarel, K. J. Russell, C. M. Ryan, S. J. Hislip, J. C. Rendall, M. X. FitzGerald, and C. M. O'Connor CD18 Dependency of Transendothelial Neutrophil Migration Differs During Acute Pulmonary Inflammation J. Immunol., September 1, 2001; 167(5): 2839 - 2846. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. U. Schraufstatter, J. Chung, and M. Burger IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways Am J Physiol Lung Cell Mol Physiol, June 1, 2001; 280(6): L1094 - L1103. [Abstract] [Full Text] [PDF]
|
|
